Abstract |
Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies. Recent evidence-based guidelines recommend the once weekly administration of epoetin beta. This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with cancer. The once-weekly administration regimen is convenient for the physician and patient alike. Methods to further optimize this treatment are discussed.
|
Authors | Dominique Spaëth |
Journal | Expert review of anticancer therapy
(Expert Rev Anticancer Ther)
Vol. 8
Issue 6
Pg. 875-85
(Jun 2008)
ISSN: 1744-8328 [Electronic] England |
PMID | 18533797
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Hematinics
- Hemoglobins
- Recombinant Proteins
- epoetin beta
- Erythropoietin
|
Topics |
- Anemia
(chemically induced, drug therapy)
- Antineoplastic Agents
(adverse effects)
- Clinical Trials as Topic
- Erythropoietin
(administration & dosage, adverse effects, therapeutic use)
- Evidence-Based Medicine
- Hematinics
(administration & dosage, adverse effects, therapeutic use)
- Hemoglobins
(drug effects, metabolism)
- Humans
- Neoplasms
(complications, drug therapy)
- Practice Guidelines as Topic
- Quality of Life
- Recombinant Proteins
- Survival Rate
|